ExodusPoint Capital Management’s Precision BioSciences DTIL Stock Holding History

ExodusPoint Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,047	Closed	-$109K	–	1828
2022 Q4	$109K	Buy	+3,047	New	+$120K	﹤0.01%	1513
2022 Q2	–	Sell	-715	Closed	-$66K	–	2047
2022 Q1	$66K	Buy	+715	New	+$97.1K	﹤0.01%	2041
2021 Q4	–	Sell	-363	Closed	-$126K	–	2254
2021 Q3	$126K	Sell	363 -448	-55%	-$152K	﹤0.01%	1876
2021 Q2	$305K	Buy	+811	New	+$244K	﹤0.01%	1728
2020 Q3	–	Sell	-1,467	Closed	-$367K	–	1854
2020 Q2	$367K	Buy	+1,467	New	+$321K	0.01%	1219
2019 Q4	–	Sell	-1,009	Closed	-$254K	–	1611
2019 Q3	$254K	Buy	+1,009	New	+$328K	0.01%	988
2019 Q2	–	Sell	-400	Closed	-$215K	–	1152
2019 Q1	$215K	Buy	+400	New	+$212K	0.02%	541

Other funds holding DTIL

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ExodusPoint Capital Management's DTIL Position: Q1 2023 in Review

ExodusPoint Capital Management sold out of Precision BioSciences (DTIL) in Q1 2023, closing a stake of 3,047 shares — an estimated $109K sold.

ExodusPoint Capital Management first reported a position in DTIL in Q1 2019 and held it in 7 quarters. The position peaked at $367K in Q2 2020. 86 funds tracked by Wall St. Rank hold DTIL as of Q1 2023.

ExodusPoint Capital Management reported no remaining Precision BioSciences position as of Q1 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 3,047 Precision BioSciences shares in Q1 2023, an estimated $109K.
ExodusPoint Capital Management first reported a position in Precision BioSciences in Q1 2019 and held it in 7 quarters.
ExodusPoint Capital Management's Precision BioSciences position peaked at $367K in Q2 2020.
86 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.